4D Announces Publication of Data Highlighting Ability of MRx0004 to Protect Against Airway Inflammation in Severe Asthma
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against […]
